BioSpace News Archive

PPD, Inc. has been recognized for the 10th consecutive year as one of the leading U.S. businesses for employee learning and development.

FibroGenesis, announced today new data supporting utilizing its fibroblast-based immunotherapy for successful inhibition and induction of regression in preclinical models of breast cancer and pancreatic cancer.

Immunovia has today published its Full Year Report for January - December 2020 . It is available on Immunovia’s website .

Currently, the Company trades on the OTC Pink Sheets under the symbol “MSSTF”.

Delfi Diagnostics, a pioneering developer of a new class of high performance, affordable liquid biopsy tests for early cancer detection, has hired Tara Maddala as Vice President of Clinical Development and Allison Ryan as Vice President of Data Science.

XORTX Therapeutics Inc. (CSE:XRX)(OTCQB:XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces that the Company is participating in the BIO CEO and Investor Digital Conference to be held virtually February 16-18, 2021.

ESMO, the leading organisation for medical oncology, launches an important new service for rapidly disseminating research to accelerate the transition of results into practice for the benefit of cancer patients.

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the completion of its previously announced underwritten public offering of 7,532,500 shares of its common stock at a price to the public of $26.75 per share, including 982,500 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares.

Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to developing innovative molecular diagnostic tests for infectious diseases at the point-of-care, today announced the closing of its previously announced initial public offering of 15,870,000 shares of its common stock, which includes 2,070,000 shares sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares,

Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at these upcoming investor conferences: SVB Leerink 10 th Annual Global Healthcare Conference February 26, 2021 Fireside chat presentation: 1:40 p.m. ET Cowen 41 st Annual Health Care Conference March 3-4, 2021 No presentation